Leadership

John Valliant, PhD

Founder

Dr. John Valliant is the founder of CPDC.  Dr. Valliant oversees the strategic directions of the scientific and commercial programs of the CPDC, to ensure the Centre’s long-term vision and sustainability.

John is currently Professor in the Department of Chemistry and Chemical Biology, at McMaster University.  He is recognized internationally for his work in radiopharmaceutical chemistry.  His current research focuses on developing novel radiolabeling methods and compound discovery strategies, in order to create clinically relevant imaging and therapeutic drug candidates.  Thus far, John has published more than 100 peer review research papers and holds 16 patents in the area of radiochemistry and radiopharmaceuticals. He completed his PhD at McMaster University, followed by a post-doctoral fellowship under the joint supervision of professors Alun G. Jones (Harvard) and Alan Davison (MIT).

John was selected as one of ‘Canada’s Top 40 Under 40’ in 2009, a distinction that recognized his exceptional work to advance radiopharmaceutical technology and education, improve patient care, and generate economic growth, through his work at the CPDC and McMaster University.  More recently he was a co-recipient of the Brockhouse Prize for Interdisciplinary Research in Science and Engineering (2015).

Justyna Kelly

Interim Chief Executive Officer

Anne Goodbody, PhD

Chief Regulatory Officer

Dr. Goodbody oversees CPDC’s regulatory functions and clinical operations. Moreover, Anne is responsible for the quality and GMP compliance of the CPDC’s manufacturing network and has lead the Centre successfully through both Health Canada and FDA audits.

Anne has over 25 years of pharmaceutical research and development experience and is recognized as a Canadian leader and expert in radiopharmaceutical regulatory affairs. Prior to the CPDC, Anne was the VP of Drug Development at Vasogen Inc., an Ontario-based Drug Developer focused on therapies for inflammatory disorders. Anne also held senior roles including VP Development at Molecular Insight Pharmaceuticals,and Director of Biological Research at Resolution Pharmaceuticals.

Anne holds a PhD in biochemistry from the University of Cambridge (UK), and has published extensively, is a named inventor on 15 issued patents and has presented research at international conferences.

Board of Directors

CPDC is governed by an independent Board of Directors. Board members represent all key sectors associated with the CPDC. The Board of Directors works with the CEO and CPDC executive team to shape the CPDC’s future direction and success.

Study gives Ontario men access to advanced prostate cancer imaging

LONDON, Ontario – Led by researchers at Lawson Health Research Institute, a multi-centre registry trial is testing the use of a new imaging tracer, called a PSMA tracer, for early detection of recurrent prostate cancer. The registry gives patients access to a new type of imaging and will assess the impact on patient care. PSMA

CPDC’s Discovery Team is experienced in oncology, immuno-oncology, and neurology models.

CPDC and University Health Network have created a joint venture, CanProbe, to accelerate the clinical development of molecular imaging probes.

CPDC’s manufacturing facilities are approved by Health Canada for the production of positron emitting radiopharmaceuticals.

Global drug companies are using CPDC’s know-how and world-class facilities to develop and test new drugs and molecular probes.

During medical isotope shortages, CPDC can provide substitutes for use in bone scans and imaging kidney function.

CPDC can create PET and SPECT imaging companions for small molecules, peptides, antibodies and other biologics.

CPDC works with all therapeutic and diagnostic isotopes, and has extensive expertise with alpha and beta emitting nuclides.

Cyclotrons can be used to produce enough Tc-99m within 6 hours to enable over 500 nuclear imaging scans.

Molecular imaging probes can show a tumour’s biochemical response to treatment in just a few days, unlike conventional modes like MRI or CT, which may not show a change in tumour size for several weeks.

ARTMS Products Inc. has been created by Triumf, BCCA, LHRI and CPDC to commercialize jointly-developed technology for production of Tc-99m on standard medical cyclotrons.

Molecular PET imaging probes are used primarily to diagnose cancer, heart disease and neurological conditions.